GO
Loading...

Abbott Laboratories

More

  • Kentucky is suing Purdue Pharma on claims that the company misrepresented its prescription painkiller, resulting in a wave of addiction and increased medical costs across the state. Kentucky officials filed theirs, which included claims that Purdue Pharma lied about the addictiveness of the drug to doctors, who then overprescribed it to an unwitting...

  • No bans on NZ dairy products after poison threat -govt Thursday, 12 Mar 2015 | 2:41 AM ET

    Countries including China, the biggest buyer of New Zealand dairy products, were not closing the door on shipments, a top official from the ministry told Reuters, as police track down the sender of letters to dairy giant Fonterra and the national farmers' group which were accompanied by infant formula laced with the pesticide 1080.. Following the announcement...

  • March 5- AbbVie Inc is to buy Pharmacyclics Inc for about $21 billion, giving it access to what is expected to be one of the world's top-selling cancer drugs and expanding its reach in the profitable oncology field. AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to Pharmacyclics stock's closing price on Wednesday. Deutsche Bank analyst...

  • *AbbVie to pay $261.25 per share in cash and stock. The deal gives AbbVie access to Pharmacyclics' cancer drugs portfolio, lessening the Chicago- based company's dependence on its rheumatoid arthritis drug Humira that accounts for most of its sales. "Imbruvica is not only complementary to AbbVie's oncology pipeline, it has demonstrated strong clinical...

  • *Best Buy climbs after results. *Citigroup to sell OneMain Financial to Springleaf Holdings. It's predicated on the fact that when you get up around new highs market participants tend to get a little vertigo, "said Art Hogan, chief market strategist at Wunderlich Securities in New York.

  • *Best Buy climbs in premarket after results. *Citigroup to sell OneMain Financial to Springleaf Holdings. "The market is naturally settling in, taking a breather until the scales tip either way to commence the next move to continued to new heights or a consolidated pullback," said Andre Bakhos, managing director at Janlyn Capital LLC in Bernardsville, New Jersey.

  • March 2- U.S. generic drug maker Mylan Inc is still on the prowl for more deals, after completing the multibillion-dollar acquisition of some of Abbott Laboratories' non-U.S. businesses just last week. The company forecast 2015 revenue of $9.6 billion to $10.1 billion and adjusted earnings of $4 to $4.30 per share. The company said it still expects to launch a...

  • March 2- Generic and specialty drugmaker Mylan Inc reported a rise in quarterly profit and revenue, driven mainly by strong demand for its generics in North America. Net profit attributable to the company's common shareholders rose to $189.2 million, or 47 cents per share, in the fourth quarter ended Dec. 31, from $180.2 million, or 45 cents per share, a year earlier.

  • Feb 17- Medical device maker Boston Scientific Corp on Tuesday said it has agreed to pay $600 million to Johnson& Johnson to settle a long-running lawsuit over Boston Scientific's 2005 acquisition of rival Guidant. J&J had sought more than $7 billion in damages after it lost a bidding war to Boston Scientific following an initial deal to buy Guidant for $21.5...

  • *Wave of inversion deals had many causes, experts say. *Earnings stripping, foreign profits seen as key. WASHINGTON, Feb 9- When a series of big U.S. companies last year moved to reincorporate abroad in inversion deals, some Republican lawmakers and tax policy critics blamed the high U.S. corporate tax rate.

  • Feb 2- Mylan Inc said it would buy Indian drugmaker Famy Care Ltd's female health businesses for about $750 million in cash and $50 million in contingent payments to expand its line of women's health products. Monday's announcement marks Mylan's second deal with an Indian drugmaker after it bought Bangalore- based Strides Arcolab's injectable drugs unit for...

  • Drugmaker AbbVie beats as Humira sales rise Friday, 30 Jan 2015 | 11:34 AM ET
    AbbVie facility in Ireland

    U.S. drugmaker AbbVie's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent.

  • Jan 30- U.S. drugmaker AbbVie Inc's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent. Excluding the charge and other special items, AbbVie earned 89 cents per share. Sales of Humira, which AbbVie inherited from Abbott Laboratories in 2013, rose to $3.36 billion in the fourth quarter ended...

  • Abbott CEO losing no sleep over stronger dollar Thursday, 29 Jan 2015 | 3:15 PM ET

    Jan 29- Abbott Laboratories' chief executive officer is not worried about the stronger dollar, telling analysts on Thursday his company will better withstand its painful effects than rivals due to its European factories and growing sales of nutritional products, medical diagnostics and medical optics. Half of its sales are in emerging markets, like China and...

  • Abbott Labs 2015 outlook in line with estimates Thursday, 29 Jan 2015 | 11:05 AM ET
    Employees walk near an Abbott Laboratories sign at the company's headquarters complex in Abbott Park, Illinois.

    Abbott Laboratories forecast full-year profit in line with analysts' estimates even as other drugmakers warned of a strong dollar hurting results.

  • Jan 29- Abbott Laboratories forecast full-year profit largely in line with analysts' estimates even as other large drugmakers have warned of a stronger dollar hurting their results. The company, which received more than 70 percent of revenue from outside the United States, said it expects 2015 earnings of $2.10- $2.20 per share, compared with the average...

  • Abbott Labs profit beats Street estimates Thursday, 29 Jan 2015 | 7:59 AM ET

    Jan 29- Abbott Laboratories reported a better-than-expected quarterly profit, helped by re-introduction in China and Vietnam of pediatric milk formula brands. The company's net earnings rose to $905 million, or 59 cents per share, in the fourth quarter from $589 million, or 37 cents per share, a year earlier. Excluding special items, Abbott earned 71 cents per...

  • Defendants in California and Massachusetts have sought to take advantage of a December ruling from the 2nd U.S. Circuit Court of Appeals in New York that narrowed the definition of insider trading, making it harder for prosecutors to pursue their cases. The challenges raise the possibility that the 2nd Circuit decision, legally binding only in New York,...

  • NEW YORK, Jan 21- For more than eight years, Johnson& Johnson has pursued billions of dollars in damages against Boston Scientific Corp after the latter won a controversial- and ultimately ill-fated- bidding war for device maker Guidant. J&J is seeking more than $7.2 billion in damages and interest from Boston Scientific as Guidant's successor, an amount that one...

  • Early movers: SNDK, HLT, MET, WWW, AAPL & more Tuesday, 13 Jan 2015 | 7:53 AM ET
    NYSE New York Stock Exchange traders markets

    Some of the names on the move ahead of the open.